Cancer, cardiovascular disease, and diabetes still have major unmet treatment needs.
R&D Focus
Small molecules and peptides for metabolic disease and oncology
Innovative Solution
Arisaph Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for cancer, cardiovascular disease, and diabetes. Its products include dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators and plaque reducers, and tumor activated pro-soft drugs.
Investment Funding
Last Funding Stage
Venture - Series Unknown
Total Funding Amount
10.M
Last Funding Amount
10.M
Last Funding Date
01-11-2013
Revenue
$1M to $10M
People
Founders
Christopher P. Kiritsy
William Bachovchin
About
Arisaph Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for cancer, cardiovascular disease, and diabetes. Its products include dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators and plaque reducers, and tumor activated pro-soft drugs. The company was founded in 1999 and is based in Boston, Massachusetts.
Products
Product
Pipeline of DPP-IV inhibitors, stable GLP-1 agonists, HDL modulators and tumor-activated prodrugs.
Demo Product or Complete Product?
Development-stage technology or ingredient platform; commercialization or clinical development is ongoing.
Something missing or incorrect on this page? Help us enrich this information
